Appendix: Clean Version of Claims Pending After Amendment

1. (Amended) A compound having a formula selected from the group consisting of:



and its pharmaceutically acceptable salts, wherein:

R_1 is optionally substituted *para*-hydroxyphenyl;

R_3 is selected from the group consisting of optionally substituted hydroxyaryls and alkoxyaryls;

R_2 is selected from the group consisting of optionally substituted loweralkyls; and

R_4 is selected from the group consisting of optionally substituted cycloalkyls.

2. (Amended) The compound of claim 1, wherein R_3 is selected from the group consisting of optionally substituted hydroxyaryls.

3. (Amended) The compound of claim 1, wherein R_3 is selected from the group consisting of optionally substituted alkoxyaryls.

4. The compound of claim 1, wherein at least one of R_1 and R_3 is substituted with at least one hydroxy or alkyloxy group.

5. (Amended) A compound having a formula selected from the group consisting of:



and its pharmaceutically acceptable salts, wherein:

R_1 is optionally substituted *para*-hydroxyphenyl;

R_3 is selected from the group consisting of optionally substituted phenyloxyloweralkyls;

R_2 is selected from the group consisting of optionally substituted loweralkyls; and

R_4 is selected from the group consisting of optionally substituted cycloalkyls.

6. The compound of claim 5, wherein at least one of R_1 and R_3 is substituted with a substituent selected from the group consisting of halogen, nitro, cyano, loweralkyl, halolowerlalky, loweralkyloxy, halololoweralkyloxy, carboxy, loweralkyloxycarbonyl, aryloxycarbonyl, (cyclololoweralkyl) oxycarbonyl, aralkyloxycarbonyl, heteroaryloxycarbonyl, heteroaralkyloxycarbonyl, (heterocyclololoweralkyl) oxycarbonyl, loweralkylsulfinyl, loweralkylsulfonyl, loweralkylthio, arylthio, loweralkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, heteroarylcarbonyloxy, heteroaralkylcarbonyloxy, (cyclololoweralkyl) carbonyloxy, alkylsulfonylamino, (heterocyclololoweralkyl) carbonyloxy, aminocarbonyl, loweraklylaminocarbolnyl, arylaminocarbonyl, aralkylaminocarbonyl, heteroarylaminocarbonyl, and heteroaralkylalminocarbonyl.

7. (Amended) The compound of claim 6, wherein at least one of R_1 and R_3 is substituted with a substituent selected from the group consisting of halogen, nitro, cyano, loweralkyl, halololoweralalkyl, loweralkyloxy, halolowerlakyloxy, carboxy, loweralkylthio, aminocarbonyl, and loweralkylsulfinyl.

8-9. (Canceled)

10. (Amended) The compound of claim 1, wherein at least one of R_1 and R_3 is substituted with at least one hydroxy or thio group.

11. (Amended) The compound of claim 1, wherein at least one of R_1 and R_3 is substituted with a substituent selected from the group consisting of halogen, loweralkyl, halolowerlalkyl, loweralkyloxy, halolowerlakyloxy, carboxy, loweralkyloxycarbonyl, aryloxycarbonyl, (cyclololoweralkyl) oxycarbonyl, aralkyloxycarbonyl, heteroaryloxycarbonyl, heteroaralkyloxycarbonyl, (heterocyclololoweralkyl) oxycarbonyl, loweralkylsulfinyl, loweralkylsulfinyl, loweralkylthio, arylthio, loweralkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, heteroarylcarbonylloxy, heteroaralkylcarbonyloxy, (cyclololoweralkyl)

carbonyloxy, (heterocycloloweralkyl) carbonyloxy, aminocarbonyl, loweralkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, heteroarylaminocarbonyl, and heteroaralkylaminocarbonyl.

12. A composition for use in treating an estrogen receptor-mediated disorder in a mammal, comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically effective carrier.